NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

鐮狀細胞貧血(SCD)- 流行病學預測 2028年

Sickle Cell Disease (SCD) - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534989
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
鐮狀細胞貧血(SCD)- 流行病學預測 2028年 Sickle Cell Disease (SCD) - Epidemiology Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

新興7個國家(土耳其、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷)的鐮狀細胞貧血(SCD)的2017年的患病數估算為14萬3,306人。

本報告提供新興7個國家(土耳其、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷)的鐮狀細胞貧血(SCD)調查,疾病概要和現行的治療方法,流行病學的預測,市場規模,各病型、臨床症狀的患病數的變化與預測,未滿足需求等資料彙整。

目錄

第1章 市場概要

第2章 鐮狀細胞貧血(SCD)的患者分佈

  • 患者分佈(實在數值、預測值)

第3章 簡介

  • 疾病背景和概要
  • 分類
  • 原因
  • 風險要素
  • 併發症
  • 症狀
  • 病理生理學
  • 診斷

第4章 主要調查結果

  • 新興7個國家的鐮狀細胞貧血(SCD)總患病數
  • 新興7個國家的鐮狀細胞貧血(SCD)診斷數

第5章 新興7個國家的鐮狀細胞貧血(SCD)的流行病學:各國

  • 假設和理論的根據
  • 沙烏地阿拉伯
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 阿拉伯聯合大公國(UAE)
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 土耳其
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 墨西哥
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 巴西
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 阿根廷
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀
  • 哥倫比亞
    • 鐮狀細胞貧血(SCD)的患病數
    • 鐮狀細胞貧血(SCD)的診斷數
    • 鐮狀細胞貧血(SCD)的患病數:各病型
    • 鐮狀細胞貧血(SCD)的患病數:各臨床症狀

第6章 鐮狀細胞貧血(SCD)的治療和管理

  • 血管閉塞症
  • 慢性疾病
  • 其他有潛力治療方法

第7章 未滿足需求

第8章 附錄

  • 調查方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0215

DelveInsight's 'Sickle Cell Disease (SCD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of SCD in the 7 Emerging Markets (EM) i.e., Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina.

Geography Covered

  • Middle East (Turkey, Saudi Arabia , UAE)
  • Latin America (Mexico, Colombia, Brazil, Argentina)

Study Period: 2017-2028

Sickle Cell Disease (SCD) - Disease Understanding

The DelveInsight Sickle Cell Disease epidemiology report gives the thorough understanding of the SCD by including details such as disease definition, classification, symptoms, risk factors, pathogenesis, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Sickle Cell Disease in the 7 Emerging Markets (EM), i.e., Turkey, Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina. Sickle Cell Disease (SCD) is the name given to a group of lifelong inherited conditions that affect hemoglobin. It is characterized as a chronic hemolytic disorder that is marked by tendency of hemoglobin molecules within red blood cells to polymerize and deform the red cell into sickle (or crescent) shape (Hb S) resulting in characteristic vaso-occlusive events and accelerated hemolysis.

Sickle Cell Disease (SCD) Epidemiology

The Sickle Cell Disease (SCD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 emerging markets. The epidemiology data for Sickle Cell Disease epidemiology are studied through all possible division to give a better understanding about the Disease scenario in 7EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Sickle Cell Disease Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Sickle Cell Disease in 7 EM, diagnosed prevalence of Sickle Cell Disease in 7 EM) scenario of Sickle Cell Disease(SCD) in the 7EM covering Turkey, , Saudi Arabia, UAE, Mexico, Colombia, Brazil, and Argentina from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, Total prevalent population of Sickle Cell Disease in 7 EM was observed to be 143,306 cases in 2017.

Report Scope

  • The report covers the descriptive overview of Sickle Cell Disease , explaining its causes and currently available therapies
  • Comprehensive insight has been provided into the epidemiology of the Sickle Cell Disease and its treatment in the 7 EM.
  • A detailed review of global historical and forecasted Sickle Cell Disease epidemiology is included in the report, covering drug all 7 EM.

Sickle Cell Disease Report Key Strengths

  • 10 Years Forecast
  • 7EM Coverage
  • Epidemiology Segmentation

Sickle Cell Disease Epidemiology Segmentation

  • Total prevalence of Sickle Cell Disease in 7 EM
  • Diagnosed prevalence of Sickle Cell Disease in 7 EM
  • Type Specific prevalence of Sickle Cell Disease in 7 EM
  • Clinical Manifestations of Sickle Cell Disease in 7 EM

Table of Contents

1. Sickle Cell Disease Market Overview at a Glance

2. Patient Share (%) Distribution of Sickle Cell Disease

  • 2.1. Patinet Share (%) Distribution of Sickle Cell Disease

3. Introduction

  • 3.1. Disease Background and Overview
  • 3.2. Classification of Sickle Cell Disease
  • 3.3. Causes
  • 3.4. Associated risk factors
  • 3.5. Complications
  • 3.6. Symptoms
  • 3.7. Pathophysiology
  • 3.8. Diagnosis
  • 3.9. Seven Emerging Markets (EM) Total Prevalent Patient Population of Sickle Cell Disease (SCD)

4. Key Findings

  • 4.1. Total Prevalence of Sickle Cell Disease in 7 Emerging Markets
  • 4.2. Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets
  • 4.3. Country Wise-Epidemiology of Sickle Cell Disease (SCD)

5. Emerging Markets: Assumptions and Rationale

  • 5.1. Saudi Arabia
  • 5.2. Total Prevalent Cases of SCD trait in Saudi Arabia
    • 5.2.1. Total Prevalent Cases of SCD in Saudi Arabia
    • 5.2.2. Diagnosed Cases of SCD in Saudi Arabia
    • 5.2.3. Type-specific prevalence of SCD in Saudi Arabia
    • 5.2.4. Clinical manifestations of SCD in Saudi Arabia
    • 5.2.5. U.A.E.
  • 5.3. Total Prevalent Cases of SCD trait in U.A.E.
    • 5.3.1. Total Prevalent Cases of SCD in U.A.E.
    • 5.3.2. Diagnosed Cases of SCD in U.A.E.
    • 5.3.3. Type-specific prevalence of SCD in U.A.E.
    • 5.3.4. Clinical manifestations of SCD in U.A.E.
    • 5.3.5. Turkey
  • 5.4. Total Prevalent Cases of SCD trait in Turkey
    • 5.4.1. Total Prevalent Cases of SCD in Turkey
    • 5.4.2. Diagnosed Cases of SCD in Turkey
    • 5.4.3. Type-specific prevalence of SCD in Turkey
    • 5.4.4. Clinical manifestations of SCD in Turkey
    • 5.4.5. Mexico
  • 5.5. Total Prevalent Cases of SCD trait in Mexico
    • 5.5.1. Total Prevalent Cases of SCD in Mexico
    • 5.5.2. Diagnosed Cases of SCD in Mexico
    • 5.5.3. Type-specific prevalence of SCD in Mexico
    • 5.5.4. Clinical manifestations of SCD in Mexico
    • 5.5.5. Brazil
  • 5.6. Total Prevalent Cases of SCD trait in Brazil
    • 5.6.1. Total Prevalent Cases of SCD in Brazil
    • 5.6.2. Diagnosed Cases of SCD in Brazil
    • 5.6.3. Type-specific prevalence of SCD in Brazil
    • 5.6.4. Clinical manifestations of SCD in Brazil
    • 5.6.5. Argentina
  • 5.7. Total Prevalent Cases of SCD trait in Argentina
    • 5.7.1. Total Prevalent Cases of SCD in Argentina
    • 5.7.2. Diagnosed Cases of SCD in Argentina
    • 5.7.3. Type-specific prevalence of SCD in Argentina
    • 5.7.4. Clinical manifestations of SCD in Argentina
    • 5.7.5. Colombia
  • 5.8. Total Prevalent Cases of SCD trait in Colombia
    • 5.8.1. Total Prevalent Cases of SCD in Colombia
    • 5.8.2. Diagnosed Cases of SCD in Colombia
    • 5.8.3. Type-specific prevalence of SCD in Colombia
    • 5.8.4. Clinical manifestations of SCD in Colombia
    • 5.8.5. Treatment and Management of Sickle Cell Disease

6. Treatment and Management of Sickle Cell Disease

  • 6.1. Vaso-occlusive crisis
  • 6.2. Chronic disease
  • 6.3. Other promising therapeutic approaches

7. Unmet Needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • Table 1: Laboratory test schedule for patients with SCD
  • Table 2: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 3: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Table 4: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Table 5: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Table 6: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Table 7: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Table 8: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Table 9: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Table 10: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Table 11: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Table 12: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Table 13: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Table 14: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Table 15: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Table 16: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Table 17: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Table 18: Clinical manifestations of SCD in Turkey (2017-2028)
  • Table 19: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Table 20: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Table 21: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Table 22: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Table 23: Clinical manifestations of SCD in Mexico (2017-2028)
  • Table 24: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Table 25: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Table 26: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Table 27: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Table 28: Clinical manifestations of SCD in Brazil (2017-2028)
  • Table 29: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Table 30: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Table 31: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Table 32: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Table 33: Clinical manifestations of SCD in Argentina (2017-2028)
  • Table 34: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Table 35: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Table 36: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Table 37: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Table 38: Clinical manifestations of SCD in Colombia (2017-2028)
  • Figure 1: Sickle Cell Disease classification
  • Figure 2: SCD complications
  • Figure 3: Common symptoms associated with Sickle Cell Disease
  • Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
  • Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
  • Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
  • Figure 7: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Figure 10: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 11: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 12: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Figure 13: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Figure 14: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Figure 15: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Figure 16: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Figure 17: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Figure 18: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Figure 19: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Figure 20: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Figure 21: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Figure 22: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Figure 23: Clinical manifestations of SCD in Turkey (2017-2028)
  • Figure 24: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Figure 25: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Figure 26: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Figure 27: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Figure 28: Clinical manifestations of SCD in Mexico (2017-2028)
  • Figure 29: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Figure 30: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Figure 31: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Figure 32: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Figure 33: Clinical manifestations of SCD in Brazil (2017-2028)
  • Figure 34: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Figure 35: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Figure 36: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Figure 37: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Figure 38: Clinical manifestations of SCD in Argentina (2017-2028)
  • Figure 39: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Figure 40: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Figure 41: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Figure 42: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Figure 43: Clinical manifestations of SCD in Colombia (2017-2028)

Figure 44 Treatment algorithm for SCD

Figure 45 Measure of pain intensity and location

  • Figure 46: Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of Sickle Cell Disease
  • Figure 47: Unmet needs for Sickle Cell Disease

List of Figures

  • Figure 1: Sickle Cell Disease classification
  • Figure 2: SCD complications
  • Figure 3: Common symptoms associated with Sickle Cell Disease
  • Figure 4: Induction of Red-Cell Sickling by Polymerization of Deoxy-hemoglobin-S
  • Figure 5: Principal Mechanisms Responsible for Potassium and Water Loss in Sickle Red Cells.
  • Figure 6: Principal Interactions Responsible for the Adhesion of a Sickle Red Cell to the Microvascular Endothelium
  • Figure 7: Total Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Sickle Cell Disease in 7 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of SCD trait in Saudi Arabia (2017-2028)
  • Figure 10: Total Prevalent Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 11: Total Diagnosed Cases of SCD in Saudi Arabia (2017-2028)
  • Figure 12: Type-specific prevalence of SCD in Saudi Arabia (2017-2028)
  • Figure 13: Clinical manifestations of SCD in Saudi Arabia (2017-2028)
  • Figure 14: Total Prevalent Cases of SCD trait in U.A.E. (2017-2028)
  • Figure 15: Total Prevalent Cases of SCD in U.A.E. (2017-2028)
  • Figure 16: Total Diagnosed Cases of SCD in U.A.E. (2017-2028)
  • Figure 17: Type-specific prevalence of SCD in U.A.E. (2017-2028)
  • Figure 18: Clinical manifestations of SCD in U.A.E. (2017-2028)
  • Figure 19: Total Prevalent Cases of SCD trait in Turkey (2017-2028)
  • Figure 20: Total Prevalent Cases of SCD in Turkey (2017-2028)
  • Figure 21: Total Diagnosed Cases of SCD in Turkey (2017-2028)
  • Figure 22: Type-specific prevalence of SCD in Turkey (2017-2028)
  • Figure 23: Clinical manifestations of SCD in Turkey (2017-2028)
  • Figure 24: Total Prevalent Cases of SCD trait in Mexico (2017-2028)
  • Figure 25: Total Prevalent Cases of SCD in Mexico (2017-2028)
  • Figure 26: Total Diagnosed Cases of SCD in Mexico (2017-2028)
  • Figure 27: Type-specific prevalence of SCD in Mexico (2017-2028)
  • Figure 28: Clinical manifestations of SCD in Mexico (2017-2028)
  • Figure 29: Total Prevalent Cases of SCD trait in Brazil (2017-2028)
  • Figure 30: Total Prevalent Cases of SCD in Brazil (2017-2028)
  • Figure 31: Total Diagnosed Cases of SCD in Brazil (2017-2028)
  • Figure 32: Type-specific prevalence of SCD in Brazil (2017-2028)
  • Figure 33: Clinical manifestations of SCD in Brazil (2017-2028)
  • Figure 34: Total Prevalent Cases of SCD trait in Argentina (2017-2028)
  • Figure 35: Total Prevalent Cases of SCD in Argentina (2017-2028)
  • Figure 36: Total Diagnosed Cases of SCD in Argentina (2017-2028)
  • Figure 37: Type-specific prevalence of SCD in Argentina (2017-2028)
  • Figure 38: Clinical manifestations of SCD in Argentina (2017-2028)
  • Figure 39: Total Prevalent Cases of SCD trait in Colombia (2017-2028)
  • Figure 40: Total Prevalent Cases of SCD in Colombia (2017-2028)
  • Figure 41: Total Diagnosed Cases of SCD in Colombia (2017-2028)
  • Figure 42: Type-specific prevalence of SCD in Colombia (2017-2028)
  • Figure 43: Clinical manifestations of SCD in Colombia (2017-2028)

Figure 44 Treatment algorithm for SCD

Figure 45 Measure of pain intensity and location

  • Figure 46: Schematic diagram of the mechanisms of action of pathophysiology based new therapeutic options for treatment of Sickle Cell Disease
  • Figure 47: Unmet needs for Sickle Cell Disease